NASDAQ · KRRO
Korro Bio, Inc.
$14.20+$0.34 (+2.45%)
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
Loading market information…
NASDAQ · QTI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
QT Imaging Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
QT Imaging Holdings, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow QT Imaging Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
QT Imaging Holdings, Inc. is dedicated to the research, development, and manufacturing of advanced automated systems for breast imaging. These innovative devices are engineered to generate high-resolution ultrasound images utilizing transmission technology. The company's core product, the QT Ultrasound Breast Scanner, offers comprehensive reflection-mode and transmission-mode visualization of a patient's breast tissue. Established in 2011, QT Imaging Holdings, Inc. maintains its headquarters in Novato, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 13, 2025 |
| -$0.40+66.67% vs estimate |
| $2.80M-0.06% vs estimate |
| Q4 2024 | Mar 31, 2025 | -$0.45 | $4.87B |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.54 | $955.97K |
|---|
THE ANALYST VIEW
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $8.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$14.20+$0.34 (+2.45%)
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
$6.37-$0.41 (-5.98%)
Cyclacel Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.93% below the high.
$1.51+$0.05 (+3.42%)
Agile Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.59% below the high.
$1.52-$0.09 (-5.59%)
China Jo-Jo Drugstores, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.22% below the high.
$0.84+$0.01 (+1.07%)
Field Trip Health Ltd.: Healthcare · Medical - Care Facilities.
$4.58+$0.22 (+5.05%)
NeuroMetrix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.17% below the high.
$0.47$0.00 (0.0%)
ProSomnus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.0% below the high.
$1.63$0.00 (0.0%)
Nexalin Technology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.71% below the high.
